Inhibikase Therapeutics, Inc. Net Fee Amt
Inhibikase Therapeutics, Inc. (IKT) had Net Fee Amt of $974.65 as of 2026-08-06, per its S-8 filed 2026-08-11.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-11
- 2026-08-06: Net Fee Amt $974.65.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-06 | $974.65 S-8 · filed 2026-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |